

## CARBOPLATIN

### INDICATION (ICD10) C54, C56, C71, C72

1. Third-line treatment of fit patients with relapsed high grade glioma.
2. Frontline chemotherapy in ovarian carcinoma.
3. Relapsed ovarian carcinoma with a 1 year or greater progression free interval after 1st line platinum based chemotherapy.
4. Metastatic endometrial carcinoma.  
PS 0, 1, 2

### REGIMEN

Day 1	<b>CARBOPLATIN</b>	AUC* 6	IV infusion	#ml glucose 5% over 30 minutes
-------	--------------------	--------	-------------	--------------------------------

\*Dose calculated by EDTA GFR or calculated  $(CrCl + 25) \times AUC$ .  
Maximum dose when using CrCl  $125 + 25 \times AUC$

# diluent and diluent volume for dose prescribed as per national standardised product specification

### CYCLE FREQUENCY AND NUMBER OF CYCLES

CNS - every 28 days for 3 to 6 cycles

Gynae - every 28 days for 6 cycles

### ANTI-EMETICS

Moderate risk day 1

### CONCURRENT MEDICATION REQUIRED

Carboplatin	Anaphylaxis treatment should be prescribed if the patient has had an anaphylactic episode previously. Dexamethasone 20mg IV bolus Chlorphenamine 10mg IV bolus H <sub>2</sub> antagonist Carboplatin should be given at a slower rate e.g. 2-4 hours.
-------------	---

### EXTRAVASATION AND TYPE OF LINE / FILTERS

Carboplatin - irritant

Filter not required

Peripheral or central line

## INVESTIGATIONS

Blood results required before SACT administration

FBC, U&E including Mg <sup>++</sup> (>0.4) and LFTs Neutrophils x10 <sup>9</sup> /L ≥1.5 (CNS patients) Neutrophils x10 <sup>9</sup> /L ≥1.0 provided patient is well (gynae patients) Platelets ≥100x10 <sup>9</sup> /L	baseline and every cycle
GFR assessed using EDTA result (BMI <19 or >30 (gynae patients) or calculated creatinine clearance at the Consultant's discretion	baseline and every cycle
Patients with hydronephrosis or serum creatinine ≥100micromol/L	baseline and every cycle
CA125 (gynae patients)	baseline and day 1 every cycle
Virology	before cycle 1 if not previously checked
Weight	baseline and every cycle

## MAIN TOXICITIES AND ADVERSE REACTIONS

Carboplatin	Ototoxicity – monitor Neurotoxicity - monitor
-------------	--

## DOSE MODIFICATIONS

### Hepatic impairment

Carboplatin

No dose adjustment is needed.

### Renal impairment

Carboplatin

GFR / calculated CrCl ≤20ml/min or ≤30ml/min with pre-existing severe renal impairment	contraindicated
--	-----------------

## REFERENCES

1. Giraud EL, de Lijster B, Krens SD, Desar IME, Boerrigter E, van Erp NP. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update. Lancet Oncol 2023; 24: e229.

Assessments

	Pre	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Ongoing
Clinical assessment	X		Pre cycle		Pre cycle	Every cycle
SACT assessment (PS and toxicities)	X	X	X	X	X	Every cycle
FBC	X	X	X	X	X	Every cycle
U&E, calcium, magnesium & LFT	X	X	X	X	X	Every cycle
CrCl	X	X	X	X	X	Every cycle
CT scan	X					At cycle 6, Inform consultant team if not booked
Informed consent	X					Verbal each cycle
Height	X					
Weight recorded	X	X	X	X	X	Every cycle